- Home
- TBLD vs ABUS Comparison
TBLD vs ABUS Comparison
Compare TBLD & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TBLD
- ABUS
- Stock Information
- Founded
- TBLD 2021
- ABUS N/A
- Country
- TBLD United States
- ABUS United States
- Employees
- TBLD N/A
- ABUS N/A
- Industry
- TBLD Investment Managers
- ABUS Biotechnology: Pharmaceutical Preparations
- Sector
- TBLD Finance
- ABUS Health Care
- Exchange
- TBLD Nasdaq
- ABUS Nasdaq
- Market Cap
- TBLD 543.1M
- ABUS 617.3M
- IPO Year
- TBLD N/A
- ABUS N/A
- Fundamental
- Price
- TBLD $17.84
- ABUS $3.48
- Analyst Decision
- TBLD
- ABUS Strong Buy
- Analyst Count
- TBLD 0
- ABUS 4
- Target Price
- TBLD N/A
- ABUS $5.50
- AVG Volume (30 Days)
- TBLD 65.2K
- ABUS 953.7K
- Earning Date
- TBLD 01-01-0001
- ABUS 03-27-2025
- Dividend Yield
- TBLD 7.01%
- ABUS N/A
- EPS Growth
- TBLD N/A
- ABUS N/A
- EPS
- TBLD N/A
- ABUS N/A
- Revenue
- TBLD N/A
- ABUS $6,171,000.00
- Revenue This Year
- TBLD N/A
- ABUS N/A
- Revenue Next Year
- TBLD N/A
- ABUS $61.99
- P/E Ratio
- TBLD N/A
- ABUS N/A
- Revenue Growth
- TBLD N/A
- ABUS N/A
- 52 Week Low
- TBLD $15.19
- ABUS $2.30
- 52 Week High
- TBLD $18.03
- ABUS $4.72
- Technical
- Relative Strength Index (RSI)
- TBLD 60.10
- ABUS 57.45
- Support Level
- TBLD $17.66
- ABUS $3.20
- Resistance Level
- TBLD $17.88
- ABUS $3.45
- Average True Range (ATR)
- TBLD 0.20
- ABUS 0.15
- MACD
- TBLD -0.01
- ABUS 0.03
- Stochastic Oscillator
- TBLD 67.07
- ABUS 72.73
About TBLD Thornburg Income Builder Opportunities Trust
Thornburg Income Builder Opportunities Trust is a diversified, closed-end management investment company. The Trust's investment objective is to provide current income. The Trust will seek to achieve its investment objective by investing, directly or indirectly, at least 80% of its Managed Assets.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.